GlassScriptPrepare for your visit
James D Mclaughlin
Cardiovascular Disease · Middletown, NY · NPI 1154316131
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$1,256.90
in general payments reported to CMS, 2019-2025 · $366 in 2025
The $366 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Who reported paying
General payments only, top 6 by amount.
- Boston Scientific Corporation $430.03
- E.R. Squibb & Sons, L.L.C. $293.88
- Amgen INC. $244.02
- Novartis Pharmaceuticals Corporation $144.57
- Kiniksa Pharmaceuticals International, Plc $43.51
- Janssen Pharmaceuticals, INC $28.57
Drugs and devices associated with these payments
Repatha Leqvio Eliquis Lux-Dx Insertable Cardiac Monitor Arcalyst Acuity Steerable Resonate El Icd Vr Mylux Patient Kit With Mobile Device Camzyos Farxiga Emblem Mri S-Icd General - Therapies
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw James Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/936970/james-d-mclaughlin